Eli Lilly (NYSE:LLY) Achieves Breakthrough Efficacy With EBGLYSS for Atopic Dermatitis in Long-Term Study
Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.
Fierce Pharma2d
Texas court decision prevents compounders from producing knockoffs of Eli Lilly's tirzepatide
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
BioSpace3d
Novo Enters the Ring in Legal Fight Against GLP-1 Compounders as Lilly Notches Victory
Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...
InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Fierce Pharma3d
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...
Modern Healthcare3d
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Fierce Healthcare2d
Eli Lilly expands telehealth access to low-cost Zepbound with Teladoc Health, LifeMD tie-ups
Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...